JPM Day Three Morning Session

JPM Day Three Morning Session

Fatigue has begun to set in here at JPM as attendees are beginning to wonder whether or not they’ll be able to get back east.  Still undaunted Diabetic Investor, is desperately hoping that the afternoon session will break the string of boring presentations witnessed this morning.  One shining light this morning was Dexcom (NASDAQ:DXCM) who continues to execute. The company provided a glimpse of their upcoming quarterly results noting that the fourth quarter was better than expected.

While Dexcom continues to move forward Diabetic Investor did note there may be a strain in their relationship with Insulet (NASDAQ:PODD) who will present this afternoon.  Dexcom and Insulet have been working together to integrate the Dexcom continuous monitoring system with Insulet OmniPod Insulin Management system.  Based on comments made by Dexcom and discussions with Insulet it seems as if each side is blaming the other as to why this project is delayed. In somewhat unusual move Dexcom’s CEO Terry Gregg publicly noted that “the ball is in Insulet’s court”.

It should be interesting to see what Insulet has to say about this subject later in the day and should add to the fireworks for what should be an interesting afternoon session as MannKind (NASDAQ:MNKD) will present shortly after Insulet is done. Also presenting this afternoon will be Intuity Medical who hopefully will provide an update on their Pogo all in one glucose monitor. As Diabetic Investor has previously reported Intuity, like all diabetes device and drug companies, appears to be caught in the FDA meat grinder.

Diabetic Investor must admit we continue to be amazed at the level of interest in MannKind.  In some respects this level of interest has been amusing as Diabetic Investor has heard several takes as to whether the recent delay at the FDA is a positive or negative indicator for MannKind. It’s even more amusing to listen to MannKind supporters who continue to believe the FDA will approve the product; MannKind will find a partner and eventually become a major player in the insulin market. The consistent theme with these folks is they will never let the facts get in the way of their feelings.  

Regardless Diabetic Investor is looking forward to Al being at the podium as one thing is for certain it won’t be boring, it might be fiction, but it won’t be boring.